Skip to main content

Table 1 Previous reports on adverse events associated with tranexamic acid in patients on maintenance dialysis

From: Oral tranexamic acid combined with low molecular weight heparin only during dialysis sessions successfully controlled chronic disseminated intravascular coagulation associated with aortic aneurysm and aortic dissection in a dialysis patient: a case report with literature review

Author Patient age and sex Mode of dialysis therapy Dosage and route of administration (weight-based dosing) Adverse events Management Days required for recovery Outcome
Kitamura et al. [20] 56, male Hemodialysis 2 g daily IV × approximately 2 weeks Visual loss Tranexamic acid discontinuation 2–3 days Partial recovery with residual visual impairment in dark places
Hui et al. [21] 61, male Peritoneal dialysis 2 g daily PO × 6 days Multifocal myoclonus Tranexamic acid discontinuation 4 days Complete recovery
Ma et al. [18] 57, male Peritoneal dialysis 1 g IV [< 15 mg/kg] Disorientation, upper extremity myoclonus, and visual disturbance Tranexamic acid discontinuation 3 days Complete recovery
Ma et al. [18] 50, female Peritoneal dialysis 6 g IV (4.5 g IV during operation and another 1.5 g IV postoperatively) [< 120 mg/kg within 12 h] Disorientation, generalized tonic-clonic convulsion Tranexamic acid discontinuation, continuous renal replacement therapy 1 week Complete recovery
Ma et al. [18] 61, male Peritoneal dialysis 3 g daily PO × 3 days [< 45 mg/kg per day] Slurring of speech, upper extremity myoclonus, unsteady gait, and visual disturbance Tranexamic acid discontinuation 3 days Complete recovery
Fuah et al. [22] 65, male Hemodialysis 2 g IV (1 g IV × 2 doses over 5 h) Generalized tonic-clonic convulsion Tranexamic acid discontinuation, intravenous diazepam 5 mg for the acute treatment of second seizure 1 day Complete recovery
  1. IV intravenous, PO per oral
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us